Compare Inovio Pharmaceuticals Inc (INO) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $116.7. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | QQQE | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $122.72 |
52-Week Low | $1.05 | $96.06 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
QQQE trades at $116.70, down 0.09% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its defensive appeal amid market shifts, with SpaceX's imminent Nasdaq-100 inclusion potentially driving passive inflows.
The outlook balances diversification benefits against market volatility risks. Equal weighting provides stability if mega-cap tech underperforms, but the bearish technical trend and neutral oscillators suggest near-term caution. Investors seeking Nasdaq exposure with lower single-stock risk may find QQQE attractive, though monitoring index rebalancing impacts is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
